Drug Type Small molecule drug |
Synonyms AP-CD/LD, AP-CDLD, Carbidopa and Levodopa + [63] |
Target |
Action inhibitors, antagonists |
Mechanism DDC inhibitors(DOPA decarboxylase inhibitors), DRDs antagonists(Dopamine receptors antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 May 1975), |
RegulationFast Track (United States), Orphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Carbidopa/Levodopa | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Parkinsonian Disorders | Japan | 14 May 1993 | |
Parkinson Disease | United States | 02 May 1975 | |
Parkinson Disease, Postencephalitic | United States | 02 May 1975 | |
Parkinson Disease, Secondary | United States | 02 May 1975 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyskinesias | Phase 3 | United States | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Finland | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Greece | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Hungary | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Italy | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Slovakia | 09 Feb 2017 | |
Dyskinesias | Phase 3 | Spain | 09 Feb 2017 | |
Neuroleptic Malignant Syndrome | Phase 3 | United States | 26 Oct 2015 | |
Neuroleptic Malignant Syndrome | Phase 3 | Australia | 26 Oct 2015 | |
Neuroleptic Malignant Syndrome | Phase 3 | Canada | 26 Oct 2015 |
Phase 1/2 | 13 | (Carbidopa Monotherapy and Carbidopa-Levodopa) | jxbcyolikd(vmgubqdjir) = pwwiqragbx ogcvvgzynj (apydzyhowi, 0.14) View more | - | 17 Jun 2025 | ||
Placebo 1 (Placebo) | jxbcyolikd(vmgubqdjir) = zprbfkdfnu ogcvvgzynj (apydzyhowi, 0.18) View more | ||||||
Phase 3 | - | 495 | jtwyommrtv(hrbhynxjsm) = sadvnaaorc hiykodfhyi (pmfiwnwnci ) | Positive | 07 Apr 2025 | ||
Immediate-Release Carbidopa-Levodopa (IR CD-LD) | jtwyommrtv(hrbhynxjsm) = sejnfrioxm hiykodfhyi (pmfiwnwnci ) | ||||||
Phase 3 | Parkinson Disease levodopa-equivalent-daily-dose (LEDD) of DA | - | mqdyxmyvrg(rmbcjkgskk) = pczdxpstlw wgxyfweupk (cwjbwyeeak ) | Positive | 07 Apr 2025 | ||
Dopamine agonist LEDD ≤200mg | mqdyxmyvrg(rmbcjkgskk) = nrjvtzseup wgxyfweupk (cwjbwyeeak ) | ||||||
Phase 3 | - | tvdwhzztfb(mdsccpnkqx) = xlkkcjyifd ssbnhuhjzc (oudvkigdin ) View more | Positive | 30 Sep 2024 | |||
NCT03670953 (FDA_CDER) Manual | Phase 3 | 630 | ibqzrnrrpk(qsplenuboh) = iuhwnwjkdq idvnkoizdk (rxhtypyzhy ) View more | Positive | 07 Aug 2024 | ||
Immediate-release carbidopa-levodopa | ibqzrnrrpk(qsplenuboh) = xnoclpxcev idvnkoizdk (rxhtypyzhy ) View more | ||||||
Phase 2 | 19 | 24h ND0612 infusion | bcrdkfocfs(uipuffqafa) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 pwjkxaakzq (wpshygxfxy ) | Positive | 28 Jun 2024 | ||
Phase 3 | - | Levodopa/carbidopa infusion (ND0612) | udejqxuvgu(oabmqfttlh) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. xojbaxrmdm (cbohkwwehm ) | Positive | 28 Jun 2024 | ||
Not Applicable | - | ejdllgsfrc(wwcjblcypc) = Most (88.1%) cases of infusion site infection were mild-Âseverity, with a median time to resolution of 15âdays. Infusion site infection led to discontinuation in only 12 (2.9%) patients. vpeiziwedl (owqafgybcu ) | - | 28 Jun 2024 | |||
Not Applicable | - | 24-hour ND0612 infusion | hjqhsrgfix(gcmgujuknr) = hnprgjzipc rfmbuuvxcc (aresdpcskj ) View more | - | 09 Apr 2024 |